30-Apr-2008 - Swedish authorities have recalled Sanofi Aventis' low molecular weight injectable blood thinner Lovenox (enoxaparin), known locally as Klexane, after four batches of the blockbuster drug were found to contain oversulfated chondroitin sulphate.
24-Apr-2008 - The US Food and Drug Administration (FDA) has revealed evidence linking the heparin contaminant with the series of reported adverse reactions, and has also now issued a warning letter to the Chinese facility at the centre of the safety scare after completing its inspection.
17-Apr-2008 - The US Food and Drug Administration (FDA) believes that the contamination of Baxter's blood thinner heparin, which has been linked to 62 deaths in the US, may have been due to the deliberate replacement of some ingredients with cheaper alternatives.
30-Mar-2008 - China's drug regulatory authority is finally responding to curb its damaged reputation by urging its local authorities to take a more proactive role in stemming what is fast becoming a global heparin contamination, sparked by material sourced in the country.
25-Mar-2008 - Cambrex Corp, the US-based manufacturer of small-molecule active pharmaceutical ingredients (APIs) and advanced intermediates for the drug industry, has announced that one of its customers is recalling a product for which Cambrex currently supplies the API.
25-Mar-2008 - The heparin recall has widened after a lot of heparin sodium USP active pharmaceutical ingredient (API) produced by Scientific Protein Laboratories (SPL) was found to contain a heparin-like contaminant.
20-Mar-2008 - The US Food and Drug Administration (FDA) has now identified the contaminant found in samples of Baxter's recalled heparin and confirmed that it is indeed linked to a Chinese manufacturing plant.
07-Mar-2008 - A US Food and Drug Administration (FDA) investigation into the recent Baxter heparin scare has uncovered a contaminant in the product that was sourcing the active pharmaceutical ingredient (API) from a Chinese manufacturer.
04-Mar-2008 - The US Food and Drug Administration (FDA) has alerted the media to the preliminary findings of its inspection of the Chinese facility that supplied the active pharmaceutical ingredient (API) for Baxter's heparin - now recalled from the market after a safety scare.